The Association of Intestinal Flora Metabolite TMAO with Non-alcoholic Fatty Liver Disease

Yuanyuan LI; Yaxian SONG; Yushan XU; Xiaofu ZENG; Hui YUAN; Zhao XU; Yan JIANG

doi:10.12259/j.issn.2095-610X.S20240210

Volume 45 Issue 2

Feb. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(2): 77-84

Yuanyuan LI, Yaxian SONG, Yushan XU, Xiaofu ZENG, Hui YUAN, Zhao XU, Yan JIANG. The Association of Intestinal Flora Metabolite TMAO with Non-alcoholic Fatty Liver Disease[J]. Journal of Kunming Medical University, 2024, 45(2): 77-84. doi: 10.12259/j.issn.2095-610X.S20240210

Citation:

Yuanyuan LI, Yaxian SONG, Yushan XU, Xiaofu ZENG, Hui YUAN, Zhao XU, Yan JIANG. The Association of Intestinal Flora Metabolite TMAO with Non-alcoholic Fatty Liver Disease[J]. Journal of Kunming Medical University, 2024, 45(2): 77-84. doi: 10.12259/j.issn.2095-610X.S20240210

Citation:

PDF( 1385 KB)

The Association of Intestinal Flora Metabolite TMAO with Non-alcoholic Fatty Liver Disease

doi: 10.12259/j.issn.2095-610X.S20240210

1.
Dept. of Endocrinology，The 1st Affiliated Hospital of Kunming Medical University
2.
Dept. of Ultrasound Medicine，Kunming Yunnan 650032，China

Received Date: 2023-10-07
Available Online: 2024-02-22
Publish Date: 2024-02-25

Abstract

Abstract

Objective To explore the role of TMAO from gut microbiota in non-alcoholic fatty liver disease （NAFLD）, we detected the serum level of TMAO and its precursor metabolites in NAFLD, as well as the expression level of Eubacterium rectum, Bacteroidetes multiforme, Lactobacillus and bifidobacterium in the intestinal flora. Methods We collected 118 subjects and divided into NAFLD group （86 cases） and healthy control group （32 cases） randomly. We also detected the serum level of TMAO and its precursor metabolites in subjects by high performance liquid chromatography tandem mass spectrometry detection （LC-MS）, and the expression of target bacterial DNA was detected by qRT-PCR. Results Serum TMAO, TMA and choline levels were significantly increased in NAFLD （P<0.05）, and liver fat content was positively correlated with TMAO （P<0.05）. The expression level of Lactobacillus and Eubacterium rectum in NAFLD group were increased （P<0.05）; the expression level of Bifidobacterium and Bacteroides multiform were decreased （P<0.05）.The serum TMAO level was positively correlated with Eubacterium rectum （r=0.280, P<0.05）, and negatively correlated with Bifidobacterium （r=-0.332, P<0.05）. Conclusion The level of TMAO in serum shows a positive correlation with NAFLD. The structure of intestinal flora in individuals with NAFLD is altered and linked to TMAO. This suggests that the intestinal flora may have a significant impact on the development of NAFLD through TMAO.
- Non-alcoholic fatty liver disease,
- TMAO,
- TMA,
- Intestinal flora

FullText(HTML)

References(26)

References

[1]	张金俊,吕梦,陈浩,等. 我国成人非酒精性脂肪性肝病患病率的meta分析[J]. 职业与健康,2023,39(21):3000-3003.
[2]	Xiao S Y,Xie W H,Zhang Y H,et al. Changing epidemiology of cirrhosis from 2010 to 2019: Results from the Global Burden Disease study 2019[J]. Ann Med,2023,55(2):2252326. doi: 10.1080/07853890.2023.2252326
[3]	Fang J,Yu C H,Li X J,et al. Gut dysbiosis in nonalcoholic fatty liver disease: Pathogenesis,diagnosis,and therapeutic implications[J]. Front Cell Infect Microbiol,2022,8(12):997018.
[4]	Nawrot M,Peschard S,Lestavel S,et al. Intestine-liver crosstalk in type 2 diabetes and non-alcoholic fatty liver disease[J]. Metabolism,2021,10(123):154844.
[5]	Wang Z,Klipfell E,Bennett B J. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J]. Nature,2011,472(7341):57-63. doi: 10.1038/nature09922
[6]	Janeiro M H,Ramírez M J,Milagro F I,et al. Implication of Trimethylamine N-Oxide (TMAO) in disease: Potential biomarker or new therapeutic target[J]. Nutrients,2018,10(10):1398. doi: 10.3390/nu10101398
[7]	Jalandra R,Dalal N,Yadav A K,et al. Emerging role of trimethylamine-N-oxide (TMAO) in colorectal cancer[J]. Appl Microbiol Biotechnol,2021,105(20):7651-7660. doi: 10.1007/s00253-021-11582-7
[8]	Tang W H,Wang Z,Kennedy D J. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease[J]. Circ Res,2015,116(3):448-455. doi: 10.1161/CIRCRESAHA.116.305360
[9]	Le ó n-Mimila P,Villamil-Ramírez H,Li X S,et al. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes[J]. Diabetes Metab,2021,47(2):101183. doi: 10.1016/j.diabet.2020.07.010
[10]	中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 中国肝脏病杂志(电子版),2010,2(4):43-48. doi: 10.3969/j.issn.1674-7380.2010.04.013
[11]	Motamed N,Faraji A H,Khonsari M R,et al. Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: A population-based study of northern Iran[J]. Clin Nutr,2020,39(2):468-474. doi: 10.1016/j.clnu.2019.02.024
[12]	Xia M F,Lin H D,Yan H M,et al. The association of liver fat content and serum alanine aminotransferase with bone mineral density in middle-aged and elderly Chinese men and postmenopausal women[J]. J Transl Med,2016,13(14):11.
[13]	薛平燕,江艳,徐玉善,等. 肠道菌群结构在非酒精性脂肪性肝病患者中的改变[J]. 昆明医科大学学报,2020,41(11):62-67. doi: 10.12259/j.issn.2095-610X.S20201120
[14]	Eslam M,Sanyal A J,George J,et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014. doi: 10.1053/j.gastro.2019.11.312
[15]	Angelico F,Baratta F,Pastori D,et al. Statins and non-alcoholic fatty liver disease[J]. Liver Int,2019,39(9):1787. doi: 10.1111/liv.14134
[16]	Polyzos S A,Kountouras J,Mantzoros C S. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics[J]. Metabolism,2019,3(92):82-97.
[17]	Cusi K,Isaacs S,Barb D,et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-Sponsored by the American association for the study of liver diseases(AASLD)[J]. Endocr Pract,2022,28(5):528-562. doi: 10.1016/j.eprac.2022.03.010
[18]	Hemmati M,Kashanipoor S,Mazaheri P,et al. Importance of gut microbiota metabolites in the development of cardiovascular diseases (CVD)[J]. Life Sci,2023,15(329):121947.
[19]	Saaoud F,Liu L,Xu K,et al. Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways[J]. JCI Insight,2023,8(1):e158183. doi: 10.1172/jci.insight.158183
[20]	Flores-Guerrero J L,Post A,Dijk P R,et al. Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease[J]. Liver Int,2021,41(10):2371-2382. doi: 10.1111/liv.14963
[21]	Chen Y M,Liu Y,Zhou R F,et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide,betaine and choline with non-alcoholic fatty liver disease in adults[J]. Sci Rep,2016,8(6):19076.
[22]	Gao X,Liu X F,Xu J,et al. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet[J]. J Biosci Bioeng,2014,118(4):476-481. doi: 10.1016/j.jbiosc.2014.03.001
[23]	Yu D X,Shu X O,Xiang Y B,et al. Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women[J]. J Nutr,2014,144(12):2034-2040. doi: 10.3945/jn.114.197533
[24]	Ji Y,Yin Y,Sun L J,et al. The molecular and mechanistic insights based on gut-liver axis: Nutritional target for non-alcoholic fatty liver disease (NAFLD) Improvement[J]. Int J Mol Sci,2020,21(9):3066. doi: 10.3390/ijms21093066
[25]	Muralitharan R R,Marques F Z. Diet-related gut microbial metabolites and sensing in hypertension[J]. J Hum Hypertens,2021,35(2):162-169. doi: 10.1038/s41371-020-0388-3
[26]	Cho C E,Taesuwan S,Malysheva O V,et al. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: Arandomized controlled trial[J]. Mol Nutr Food Res,2017,61(1):1600324. doi: 10.1002/mnfr.201600324

Relative Articles(20)

Relative Articles

[1]	Aiyun WANG, Yuting WANG, Jing CAI, Ruoyan NI, Caiying LUO, Zhuo YU, Peng CHEN. The Role of Intestinal Flora and Its Metabolites in The Development of Atherosclerosis. Journal of Kunming Medical University, 2024, 45(12): 1-7.
[2]	Bo LI, Yang SUN, Yinglei MIAO. Intestinal Microecological Changes and Therapeutics in Inflammatory Bowel Disease. Journal of Kunming Medical University, 2024, 45(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20240401
[3]	Zhongshun NIE, Yinglei MIAO. Prospects of Fecal Microbiota Transplantation for Inflammatory Bowel Disease in the Context of Biological Agents. Journal of Kunming Medical University, 2024, 45(10): 147-154. doi: 10.12259/j.issn.2095-610X.S20241023
[4]	Hang CHEN, Qi CUI, Minshan HUANG, Jianjun LIU, Lanqing MA. Research Progress of miRNA in Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2024, 45(1): 1-7. doi: 10.12259/j.issn.2095-610X.S20240101
[5]	Junjie NIU, Wenjuan JI, Zhuaizhuai YU. Correlation between Gut Microbiota，Serum ET，PCT Levels with the Severity and Prognosis of Sepsis. Journal of Kunming Medical University, 2024, 45(4): 140-145. doi: 10.12259/j.issn.2095-610X.S20240420
[6]	Chun LI, Qiong ZHOU, Cong MEI, Jie jie HUANG, Yi peng WANG, Song lan ZHOU, Qian ZHENG, Zhe TANG. Effect of Bifidobacterium trisporus on Intestinal Microbiota in the Mouse Model of Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2023, 44(10): 77-82. doi: 10.12259/j.issn.2095-610X.S20231022
[7]	Lin XU, Kaicheng GAO, Jie JIA, Yuyang LI, Huawei WANG, Yiqun KUANG, Yu ZHAO. Effect of Shen-ling-bai-zhu-san on Methamphetamine-Induced Gut Microbiota Change in Mice. Journal of Kunming Medical University, 2023, 44(8): 37-43. doi: 10.12259/j.issn.2095-610X.S20230829
[8]	Caihong LIANG, Mingyao MENG, Xinxin LI, Jingjing XIONG, Meng LI, Mei LIU, Zongliu HOU, Yongkun HUANG. Effect of Intestinal Flora Metabolites Deoxycholic Acid on the Proliferation and Cell Cycle of Human Umbilical Cord Mesenchymal Stem Cells. Journal of Kunming Medical University, 2023, 44(4): 23-30. doi: 10.12259/j.issn.2095-610X.S20230402
[9]	Shaoyou DENG, Yulan ZHAO, Peijin WANG, Rong LI, Jintao LI, Hong ZHENG. Effects of Osteoking Combined with Antibiotic Cocktail on Insulin Resistance and Gut Flora in db/db Mice. Journal of Kunming Medical University, 2023, 44(5): 12-18. doi: 10.12259/j.issn.2095-610X.S20230530
[10]	Dan LI, Xulian WAN, Lvyu LI, Yu YUN, Guangyun LUO, Weibing LIU, Gongfu LIN, Ning LI, Yongkun LI, Weigang DUAN. Intestinal Flora in Uricase-Deficient Rats. Journal of Kunming Medical University, 2023, 44(2): 27-32. doi: 10.12259/j.issn.2095-610X.S20230205
[11]	Xuemin ZHANG, Yunfen TIAN. Role of Abnormal Bile Acid Metabolism in the Development of Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2023, 44(11): 164-169. doi: 10.12259/j.issn.2095-610X.S20231125
[12]	Lu LI, Yunfen TIAN. Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children. Journal of Kunming Medical University, 2023, 44(7): 148-155. doi: 10.12259/j.issn.2095-610X.S20230708
[13]	Shunhang YANG, Jiongming LI, Jianhe LIU, Guang WANG, Pei LI. Progress in Pathogenesis and Treatment of Enteric Hyperoxaluria. Journal of Kunming Medical University, 2022, 43(7): 152-155. doi: 10.12259/j.issn.2095-610X.S20220734
[14]	Yongrui YANG, Liyuan WANG, Haiwen LI, Zhirong ZHAO, Rui PU, Guishuai WU, Shude LI. Scutellarin Ameliorates Liver Fibrosis in Nonalcoholic Fatty Liver Disease by Inhibiting NOX Expression. Journal of Kunming Medical University, 2022, 43(7): 38-45. doi: 10.12259/j.issn.2095-610X.S20220721
[15]	Sixiang LIU, Yongkun HUANG, Mingying WANG, Hongwei HU, Min MA, Yu LING. Analysis of Intestinal Flora and Therapeutic Intervention in Children with Functional Constipation. Journal of Kunming Medical University, 2022, 43(3): 123-127. doi: 10.12259/j.issn.2095-610X.S20220309
[16]	Sheng-hao LI, Jie DING, Qing-qing WANG, Si-qi LIU, Li-juan HUA, Jin-yu DUAN, Bao-li BO, An-rui DU, Guo-ji CHANG, Jun-yi LI. Influencing Factors of Moderate to Severe Liver Injury in Patients with Chronic Hepatitis B and NAFLD. Journal of Kunming Medical University, 2021, 42(7): 77-82. doi: 10.12259/j.issn.2095-610X.S20210712
[17]	Yong-fang XU, Na WU, Yue-xin HU, Yong-mei ZHAO, Shao-ding ZHENG, Ling WEI, Si-jia ZHENG, Jian-jun LIU. Therapeutic Effect of GW7647 on Non-alcoholic Fatty Liver Disease in Rats. Journal of Kunming Medical University, 2021, 42(8): 17-22. doi: 10.12259/j.issn.2095-610X.S20210804
[18]	Tang Juan , Nian Xin . . Journal of Kunming Medical University, 2020, 41(03): 137-143.
[19]	Liang Rui , Chun Yu Wei Xun , Shen Dao , Sun Le , Li Yun Feng . . Journal of Kunming Medical University, 2020, 41(06): 156-161.
[20]	Ping-yan XUE, Yan JIANG, Yu-shan XU, Hui YUAN, Xuan LI, Ya-xian SONG, Hua LIU. Changes of Intestinal Flora in Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2020, 41(11): 62-67. doi: 10.12259/j.issn.2095-610X.S20201120